DINAMIQS

Executive Summary

DINAMIQS is a Swiss contract development and manufacturing organization (CDMO) specializing in viral vector production for cell and gene therapies, with a focus on adeno-associated virus (AAV) and lentivirus vectors. Founded in 2019 and based in Zurich, the company offers end-to-end services from early-stage development through commercial-scale cGMP manufacturing. By positioning itself as a science-driven partner, DINAMIQS aims to de-risk and accelerate the development of genetic medicines. The company operates in a rapidly growing market, driven by increasing approvals of gene therapies and the need for specialized manufacturing capacity. While still private and relatively young, DINAMIQS benefits from Switzerland's strong biotech ecosystem and the global demand for high-quality viral vectors. Its ability to secure partnerships with emerging gene therapy developers and established pharmaceutical companies will be key to its growth trajectory.

Upcoming Catalysts (preview)

• Q2 2026Securing a commercial-scale manufacturing contract with a late-stage gene therapy developer40% success
• Q4 2026Announcement of capacity expansion or new facility to meet growing demand50% success
• Q3 2026Strategic partnership with a large pharmaceutical company for AAV or lentivirus platform development35% success